An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults

BACKGROUND: Edoxaban is an orally active, direct factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation and for the treatment of venous thromboembolism. OBJECTIVES: This study assessed the pharmacokinetics, safety, and tolerability of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Duchin, Kenneth, Duggal, Anil, Atiee, George J., Kidokoro, Motonori, Takatani, Tadanobu, Shipitofsky, Nicole Lazarus, He, Ling, Zhang, George, Kakkar, Tarundeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784001/
https://www.ncbi.nlm.nih.gov/pubmed/28512699
http://dx.doi.org/10.1007/s40262-017-0554-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784001/
https://www.ncbi.nlm.nih.gov/pubmed/28512699
http://dx.doi.org/10.1007/s40262-017-0554-0

Ejemplares similares